Rejoy Health vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W21 AI patient education for thyroid and chronic conditions at $125M valuation Sep 2024; $22.2M from Google, Harvard endowment, Gaingels/YC competing with Paloma Health for AI-driven medical knowledge accessibility for underdiagnosed chronic disease.
About
Rejoy Health is a San Francisco-based AI-powered healthcare platform — backed by Y Combinator (W21) with $22.2 million in total funding from Y Combinator, Google, Gaingels, and the Harvard University endowment fund, achieving a $125 million valuation in September 2024 — providing patients with chronic conditions (particularly thyroid disorders) with AI-driven medical knowledge accessibility tools and subscription-based treatment and management services that bridge the gap between patient symptoms, lab results, and clinical recommendations. Founded in 2020 by former Facebook and Microsoft engineers and launched through Y Combinator, Rejoy translates complex medical information into personalized, understandable patient guidance using artificial intelligence.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.